(Q37717901)

22 August 2017

1 reference

title

Heterogeneous vancomycin resistance in Staphylococcus aureus: a review of epidemiology, diagnosis, and clinical significance (English)

1 reference

22 August 2017

0 references

1 reference

Staphylococcus aureus

1 reference

1 reference

Star L Rong

1

1 reference

22 August 2017

Steven N Leonard

series ordinal

2

1 reference

22 August 2017

language of work or name

English

0 references

publication date

23 March 2010

1 reference

Annals of Pharmacotherapy

22 August 2017

published in

1 reference

22 August 2017

volume

44

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

844-850

1 reference

Genomic analysis reveals a point mutation in the two-component sensor gene graS that leads to intermediate vancomycin resistance in clinical Staphylococcus aureus

22 August 2017

cites work

1 reference

Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA).

21 January 2018

1 reference

Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia

21 January 2018

1 reference

A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital

21 January 2018

1 reference

Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007).

21 January 2018

1 reference

Vancomycin treatment failure associated with heterogeneous vancomycin-intermediate Staphylococcus aureus in a patient with endocarditis and in the rabbit model of endocarditis

21 January 2018

1 reference

Antimicrobial resistance in intensive care units

21 January 2018

1 reference

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

21 January 2018

1 reference

Staphylococcus aureus with Heterogeneous Resistance to Vancomycin: Epidemiology, Clinical Significance, and Critical Assessment of Diagnostic Methods

21 January 2018

1 reference

Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus.

21 January 2018

1 reference

Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia

21 January 2018

1 reference

Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus

21 January 2018

1 reference

Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy

21 January 2018

1 reference

Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus

21 January 2018

1 reference

Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia

21 January 2018

1 reference

Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center

21 January 2018

1 reference

Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin.

21 January 2018

1 reference

Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.

21 January 2018

1 reference

Control and outcome of a large outbreak of colonization and infection with glycopeptide-intermediate Staphylococcus aureus in an intensive care unit

21 January 2018

1 reference

The prevalence and mechanisms of vancomycin resistance in Staphylococcus aureus.

21 January 2018

1 reference

Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know

21 January 2018

1 reference

A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).

21 January 2018

1 reference

Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides

21 January 2018

1 reference

A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides

21 January 2018

1 reference

Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.

21 January 2018

1 reference

Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides

21 January 2018

1 reference

Unstable vancomycin heteroresistance is common among clinical isolates of methiciliin-resistant Staphylococcus aureus

21 January 2018

1 reference

Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore

21 January 2018

1 reference

Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility

21 January 2018

1 reference

Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.

21 January 2018

1 reference

Clinical isolate of vancomycin-heterointermediate Staphylococcus aureus susceptible to methicillin and in vitro selection of a vancomycin-resistant derivative

21 January 2018

1 reference

Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus

21 January 2018

1 reference

Differences in ability of cell-wall antibiotics to suppress emergence of rifampicin resistance in Staphylococcus aureus.

21 January 2018

1 reference

Associations between the genotypes of Staphylococcus aureus bloodstream isolates and clinical characteristics and outcomes of bacteremic patients

21 January 2018

1 reference

High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands

21 January 2018

1 reference

hVISA/VISA: diagnostic and therapeutic problems.

21 January 2018

1 reference

Activity of telavancin against Staphylococcus aureus strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates

21 January 2018

1 reference

Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations

21 January 2018

1 reference

Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists

21 January 2018

1 reference

Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity

21 January 2018

1 reference

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model

21 January 2018

1 reference

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis

21 January 2018

1 reference

Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin

21 January 2018

1 reference

In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model

21 January 2018

1 reference

In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1M526

1 reference

22 August 2017

1 reference